Zhenyu Xu sold $145k of SOPH
Chief Scientific Officer at SOPHiA GENETICS SA. 20,000 shares at an average of $7.25, traded Aug 5, 2026, filed Aug 7, 2026.
Score components
- +15RoleOfficer
- +11Trade size$145k at market
- 0Share of holdings soldSold 3.3% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001840706-26-000275, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | MOption exercise Ordinary Shares10b5-1 | +3,000 | $3.28 | $9,840 | 603,887 | Aug 7, 2026 |
| Aug 5, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -3,000 | $7.00 | $21k | 600,887 | Aug 7, 2026 |
| Aug 7, 2026 | MOption exercise Ordinary Shares10b5-1 | +7,000 | $3.28 | $23k | 607,887 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -7,000 | $7.02 | $49k | 600,887 | Aug 7, 2026 |
| Aug 7, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $7.48 | $75k | 590,887 | Aug 7, 2026 |
| Aug 5, 2026 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -3,000 | $3.28 | $9,840 | 7,000 | Aug 7, 2026 |
| Aug 7, 2026 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -7,000 | $3.28 | $23k | 0 | Aug 7, 2026 |
Related signals
Other insiders at SOPHiA GENETICS SA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 21, 2026 | SOPHiA GENETICS SA | Philippe Menu Chief Medical Officer | $36k 5,000 shares | -2% | |
| Pro nowfree Oct 21, 2026 | SOPHiA GENETICS SA | Zhenyu Xu Chief Scientific Officer | $29k 4,000 shares | -1% | |
| Pro nowfree Oct 21, 2026 | SOPHiA GENETICS SA | Jurgi Camblong Executive Chairman | $62k 8,500 shares | -0% | |
| 17Weak | SOPHiA GENETICS SA | George Cardoza Chief Financial Officer | $13k 1,592 shares | -1% | |
| 30Weak | SOPHiA GENETICS SA | Jurgi Camblong Executive Chairman | $327k 40,172 shares | -1% | |
| 17Weak | SOPHiA GENETICS SA | Philippe Menu Chief Medical Officer | $60k 7,394 shares | -4% | |
| 29Weak | SOPHiA GENETICS SA | Ross Muken Chief Executive Officer | $80k 9,838 shares | -1% | |
| 30Weak | SOPHiA GENETICS SA | Kevin Puylaert Chief Sales Officer | $1,737 216 shares | -0% | |
| 17Weak | SOPHiA GENETICS SA | Zhenyu Xu Chief Scientific Officer | $60k 7,394 shares | -1% | |
| 16Weak | SOPHiA GENETICS SA | Abhimanyu Verma Chief Technology Officer | $43k 5,284 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.